|
業務類別
|
Biotechnology |
|
業務概覽
|
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America. |
| 公司地址
| Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800 |
| 電話號碼
| +32 15342900 |
| 傳真號碼
| +32 15342901 |
| 公司網頁
| https://www.glpg.com |
| 員工數量
| 452 |
| Mr. Fred Blakeslee |
General Counsel and Executive Vice President |
-- |
26/03/2026 |
| Ms. Tania Philipp |
Chief Human Resources Officer |
-- |
26/03/2026 |
| Mr. Aaron L. Cox |
Chief Financial Officer and Executive Vice President |
-- |
26/03/2026 |
| Mr. Henry O. Gosebruch |
Director and Chief Executive Officer |
-- |
26/03/2026 |
|
|
| Mr. Devang Bhuva |
Director |
26/03/2026 |
| Ms. Dawn A. Svoronos |
Independent Director |
26/03/2026 |
| Dr. Jane Veronica Griffiths |
Independent Director |
26/03/2026 |
| Mr. Neil Johnston |
Independent Director |
26/03/2026 |
| Dr. Linda Higgins, PhD |
Director |
26/03/2026 |
| Mr. Henry O. Gosebruch |
Director and Chief Executive Officer |
26/03/2026 |
| Mr. Oleg Nodelman |
Director |
26/03/2026 |
| Mr. Gino Santini |
Chairman of the Board |
26/03/2026 |
|
|
|
|
